Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AKBA................MULN..............................https://stockcharts.com/h-sc/ui?s=AKBA&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
$IVDN (16 million float) News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth
PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html
ALCOHOL! New Video PlantX CEO Sean Dollinger Spills Secrets
in Interview with Michael Nauss!
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections
NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully excreted, unmetabolized, in the urine
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation in Complicated Urinary Tract Infection (cUTI) and Pyelonephritis
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin. Antibiotics commonly used to treat complicated urinary tract infections (cUTI) are associated with pseudomembranous colitis caused by Clostridium difficile (C diff) and vaginal yeast infections, primarily owing to their impact on normal flora.
C. diff causes an intractable diarrhea in approximately 500,000 Americans each year and kills 1 in 11 Americans over age 65 who contract the infection. Costs of C. diff are estimated at $24,000 per patient and are significantly higher when C. diff occurs as part of a hospital admission. Whereas most antibiotics have substantial effect in the large bowel, the key component of NRX-101 (D-cycloserine) is entirely absorbed in the small intestine and excreted unmetabolized in the urine. If the nonclinical data reported today are replicated in patients, NRX-101 could represent the first antibiotic for cUTI and pyelonephritis that has essentially no risk of causing C. diff infection or vaginal yeast infection. There is an extensive literature surrounding the use of D-cycloserine to treat tuberculosis and cases of C. Diff are unknown.
D-cycloserine's effect as an antibiotic is based on its propensity to substitute for the amino acid alanine in the formation of the bacterial cell wall.
Dr. Michael Manyak, noted Professor of Urology and former Global Medical Director for Urology at Glaxo SmithKline stated "As a Urologist, I'm acutely aware of the importance of avoiding common side effects of current antibiotics. NRX-101's lack of impact on normal flora could potentially confer a distinct advantage for the product in for the treatment of cUTI and pyelonephritis. This profile could change the lives of the half million Americans each year who contract C. diff and save lives among the tens of thousands who die from antibiotic-induced C. diff infections. These potential advantages should make NRX-101 even more attractive to potential partners in this multi-billion-dollar market." Dr. Manyak serves as NRx's Medical Thought Leader for urology.
"While we have primarily focused on NRX-101 as a drug to treat CNS disease, these new and highly provocative findings suggest that NRX-101 could find a home as a first line treatment for cUTI and pyelonephritis, which afflicts more than 3 million Americans each year. Should the rodent model findings prove applicable to the people, the use of NRX-101 to treat cUTI without increasing the risk of C. diff infection could have multibillion dollar potential," said Stephen Willard, JD, Chief Executive Officer of NRx pharmaceuticals.
About D-Cycloserine in cUTI
The active antibiotic ingredient of NRX-101 is D-cycloserine (DCS) that was developed as an antibiotic in the 1950's and used worldwide for the treatment of tuberculosis. However, it fell out of favor with the development of trimethoprim/sulfa and various penicillins, cephalosporins, and tetracyclines, in part because of the CNS effects associated with DCS-induced blockade of the brain's NMDA receptor. In the course of its CNS research, NRx Pharmaceuticals has demonstrated that small doses of lurasidone counteract those CNS effects, potentially providing a new therapeutic life to DCS as an antibiotic. Over the ensuing decades, increased antibiotic resistance has rendered standard treatments for UTI ineffective in many cases and today 3 million Americans suffer from cUTI requiring increasingly toxic antibiotics, increasingly frequent intravenous therapy, and increased need for hospital admission. (Lodise TP, et. al. Open Forum Infectious Diseases https://doi.org/10.1093/ofid/ofac307)
Because DCS has the unique property of being highly concentrated, unmetabolized, in the urine with oral administration, the Company believes, and previous literature has suggested that DCS may effectively treat, and therefore help prevent, the need for intravenous and inpatient treatment of cUTI.
Moreover, because DCS is rapidly absorbed and excreted in the urine, NRX-101 has now been shown to have minimal tendency to disrupt the microbiome of the intestine and vagina and which can lead to secondary Clostridium difficile and/or yeast infections. C. diff associated colitis doubles hospital mortality and costs the American healthcare system up to $1.6 billion each year. (Drozd EM, et. al. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection DOI: 10.1097/IPC.0000000000000299) Additionally, DCS has no known association pulmonary fibrosis, a rare, lethal condition that has been associated with macrolide (tetracycline family) antibiotics.
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations in Complicated Urinary Tract Infection and Pyelonephritis.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL90042&sd=2024-04-17 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-new-data-on-nrx-101-demonstrating-no-damage-to-intestinal-and-vaginal-flora-in-validated-rodent-models-compared-to-standard-antibiotics-potential-implications-for-avoidance-of-c--302119157.html
SOURCE NRx Pharmaceuticals, Inc.
$NBIO - Mr. Carrick continued, "Phase I demonstrated an excellent safety profile at various doses. Phase II will be focused on clinical outcomes, and we are taking no shortcuts."
https://finance.yahoo.com/news/nascent-prepares-pivotal-phase-ii-120000620.html
$GSAC
🚨 $GSAC Next trip runner!
*1.2B float
*No dilution in recent months
*Added 1.2B shares to restricted 👀
- Catalysts:
*Talking about more announcements in the near future related to the acquisition
*upcoming annual report
*Expecting to establish a new research in south africa https://t.co/Z75TJ2uVDU pic.twitter.com/k8Yll9iocq
— NarutOTC (@NarutOTC_) April 11, 2024
To connect with the previous post - the start of PlantX, present status and thoughts
about the companies future growth.
$GTVH - This acquisition will transition ABI Create into a wholly owned subsidiary of Lavish Entertainment and bolster its position in the entertainment industry through ABI’s longstanding and exceptional reputation.
https://finance.yahoo.com/news/lavish-entertainment-inc-expands-presence-120000781.html
$AVRW New and Perfect Skincare Products. #OTCQB subisdiary@Seratopical
Solutions "Harmony Toner" Available on the Seratopical Website! Great video below with Facial Plastic Surgeon Dr. Michael Persky https://seralabshealth.com/products/ $JNJ $CVS $AMZN
$VVPR - VivoPower International PLC is pleased to confirm that its subsidiary Tembo e-LV B.V. has now met all of the milestones required to obtain the investment into Tembo, at a pre-money valuation of US$120M. The initial tranche has been received.
https://finance.yahoo.com/news/vivopower-secures-full-us-10m-111500807.html
$AGBA - The challenges faced in 2023 prompted successful changes to AGBA's business model, resulting in increased focus and efficiency. The implementation of significant cost-cutting measures is expected to reduce normalized operating expenses to a level for strong growth and profitability.
https://www.marketwatch.com/press-release/agba-group-is-positioned-for-hong-kong-s-rebounding-macro-environment-with-business-refinements-and-growth-strategies-f566e8f4
New directors 400 million accumulation
undervalued overlooked until its not
$GSAC #newdirectors #Update pic.twitter.com/NyEYyzVMdL
— Johnny President (@zarproductions1) February 27, 2024
STRONG BUY barchart.com Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions. Long term indicators fully support a continuation of the trend. barchart.com PlantX will finally bounce back!
OTC: $TREIF CSE: $TRUE -- THE WORLD’S MOST INTELLIGENT, PERSONALIZED HEALTHCARE AI ENGINE https://treatment.com/investors/
$NXGB - Total years sales to be in the region of $1.3-$1.6m from the Mad House brand.
https://finance.yahoo.com/news/nxgen-brands-inc-releases-bullish-123000349.html
$GVH -Experience Effortless E-commerce Shipping: Globavend Holdings Limited (NASDAQ:GVH) Tailored Solutions from Hong Kong to Your Doorstep in Australia & New Zealand!
Click here: https://axecapitalusa.com/gvh/
Welcome to the future of logistics with Globavend Holdings Limited (NASDAQ:GVH), where innovation meets opportunity in the bustling e-commerce landscape of Asia-Pacific. As pioneers in direct injection from Hong Kong & Southern China to Australia and New Zealand, we offer investors a gateway to a market projected to witness exponential growth. Our integrated cross-border logistics solutions ensure seamless parcel consolidation, air freight forwarding, and customs clearance, catering to the evolving needs of online businesses.
Strategic Expansion: With plans to establish ground transportation and customs clearance teams, we are poised to capture a significant market share.
Profitable Partnerships: As an IATA-accredited cargo agent with strong ties to top air freight carriers, we guarantee cost-effective solutions.
Robust Growth: Amidst a booming e-commerce market, our stable business model promises lucrative returns for investors seeking long-term opportunities.
Innovative Solutions: Our all-in-one shipping solution ensures operational efficiency and customer satisfaction, positioning us as industry leaders.
Invest in Globavend today and be part of a transformative journey reshaping the future of global logistics.
$CBMJ Targets $5/7/$14..Chart reset for next move up!
PATRIOT.TV Gaining More Viewers Daily.
Watch: https://patriot.tv/
Technical chart PlantX; https://www.barchart.com/stocks/quotes/PLTXF/opinion (OTC/CAN)
See the jump about a month ago - this one is ready for some serious moves IMO.
Canadian stockexchange; https://www.barchart.com/stocks/quotes/VEGA.CN/opinion
bottoms..............................SNAX......GRDI....ZVIA........MULN........https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=ZVIA&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=GRDI&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=SNAX&p=W&b=5&g=0&id=p84354014936
VZLA.......LLAP.......MULN..........................https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=VZLA&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=LLAP&p=W&b=5&g=0&id=p84354014936
AKBA.....MULN...............................https://stockcharts.com/h-sc/ui?s=AKBA&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
$TMSH Get in P*ssies - We going old school
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174121841
MULN...........................CZOO................................https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=CZOO&p=W&b=5&g=0&id=p84354014936
$PRDL bottom is in filings on the way
$PRDL absolutely. Virtually the same exact chart as many of Frank's other tickers. I could point out lots of bullish attributes to these charts, such as the bullish divergence in the momentum indicators vs the price action. The price has trended downwards for the past couple… pic.twitter.com/NiopEwZWCn
— Professor Brainiac (@ChartDiligence) March 17, 2024
Rise n Shine $GSAC
$GSAC
Should see viable updates soon.
🧱 Updated phone #
🧱 Updated address
🧱 Updated 4 new Directed added pic.twitter.com/QJzu6P0y90
— AANTONIO (@tha_builder)
MULN......................CZOO.............................https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=CZOO&p=W&b=5&g=0&id=p84354014936
The last month more then 100% gain...! Yes, check the chart and consider,
do you want to participate in the uptrend or not?
This is my view and I don`t have all the facts, still while doing due diligence,
looking at the recent chart it looks good. Risk/reward ratio looks strong.
What is also a huge factor; the coming spring and summer month -
this sector always do better in this part of the year.
Finally, we have a strong stock market overall, check the latest reports,
with a election year it will grow even more.
Employment numbers etc are positive, I see to the facts and not politics,
when investing - mind and not emotions must rule.
https://www.barchart.com/stocks/quotes/PLTXF/overview
GLTA,
Do always your own research - this is my opinion, I`m a retail investor, not a pro..
BULLISH
HOUR........MULN....................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=HOUR&p=D&yr=0&mn=3&dy=0&id=p11960084343
MERGER? $GSAC
$GSAC after a long silence they just added 1.2B shares to restricted. A merger is coming? 🤔
— VC (@veronika_1288) March 18, 2024
TSHA..........................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
$NBIO - HypoSpray Pharma of Palm Beach Gardens FL has developed innovative technology for delivering active ingredients across the skin and mucosa. The company has a Drug Master File of record with the FDA for its delivery system.
https://finance.yahoo.com/news/nascent-collaborates-hypospray-pharma-proprietary-120000958.html
Techncal Chart 100% BUY
https://www.barchart.com/stocks/quotes/ESM.TO/overview
💲$CBMJ~~CBMJ's Patriot.TV Welcomes Former US Congressman and Syndicated Broadcaster Jason Lewis as Host on Network Lineup; Brannon Howse Joins in Inaugural Show from Newly Built State of The Art Studio
https://www.accesswire.com/837349/cbmjs-patriottv-welcomes-former-us-congressman-and-syndicated-broadcaster-jason-lewis-as-host-on-network-lineup-brannon-howse-joins-in-inaugural-show-from-newly-built-state-of-the-art-studio
Press Release | 02/28/2024
VENICE, FL / ACCESSWIRE / February 28, 2024 / Conservative Broadcast Media & Journalism (OTC PINK:CBMJ) is pleased to announce that Patriot.TV proudly announces the addition of Jason Lewis, a distinguished drive time television host, to its roster. Jason Lewis is a seasoned broadcaster, former frequent guest host for Rush Limbaugh, and esteemed former member of the U.S. Congress.
JASON LEWIS LIVE
Jason Lewis garnered widespread recognition during his tenure at AM 1500 KSTP in the prominent Minneapolis/St. Paul market, commencing in 1994. Notably, in 2007, he stood out as one of the most frequently featured guest hosts for the renowned broadcaster, Rush Limbaugh. Subsequently, from 2009 until 2014, Jason hosted his own syndicated radio program. His illustrious career trajectory led to his election to the U.S. House of Representatives in 2016. In 2020, he emerged as the Minnesota Republican nominee for the U.S. Senate, narrowly missing victory in a historically challenging electoral landscape.
In a momentous occasion, President and Chief Operating Officer of Patriot.TV, Brannon Howse, joined Jason Lewis on his inaugural program on Monday night, February 26, 2024, extending a warm welcome to him on behalf of the network.
The inaugural show can be viewed at https://patriot.tv/programs/jason-lewis-live-02-26-2024-scotus-takes-on-big-tech-censorship-repeal-section-230?category_id=195658
Howse expressed his profound enthusiasm, stating, "Jason Lewis was the first individual I contacted upon assuming the role of President and Chief Operating Officer of Patriot.TV. Having known Jason personally for over two decades, I've engaged in numerous conversations with him regarding his potential return to the airwaves. This time everything lined up perfectly and I could not be more pleased."
Furthermore, Howse emphasized the network's commitment to excellence, remarking, "At Patriot.TV, we are setting the standard for conservative broadcast networks. From the unparalleled expertise of our talent to our cutting-edge broadcast production facilities, we are unmatched in today's conservative media landscape. The state-of-the-art studio in Florida that we built for Jason Lewis, complete with a sophisticated news desk and advanced camera technology, epitomizes our dedication to quality."
Illustrating the network's distinctive edge, Howse elaborated, "Our control room operators and production team operate on the latest equipment across two control rooms, supported by a graphics and production team that rivals any competitor. The recognition of our superior standards was underscored recently when a seasoned broadcaster expressed a desire to align with our team. In the coming weeks, we are excited to unveil the exceptional talent joining Patriot.TV."
During his inaugural program, Jason Lewis reflected on his transition from quasi-retirement, he underscored the critical juncture facing the nation in 2024, emphasizing the urgency to effect substantial change.
Jason Lewis elucidated, "Brannon Howse has been after me for a few years to do something like this. And when I saw the team, he put together his vision for Patriot.tv, I finally decided this was the right opportunity. So, Brannon Howse is the guy who convinced me to do this. And he's also the guy who is formulating this new network for people who want to save America. It's as simple as that. when I saw this team that Brannon Howse and General Michael Flynn were building, I said, 'all right, for 2024 and beyond, it's time to move the needle.'"
As part of the recently acquired assets from LTV Streaming, CBMJ recently acquired the platform Patriot.TV., a subscription-based streaming service.
About CBMJ: (CBMJ) Conservative Broadcast Media and Journalism is a media and web-based Patriot Company.
$NRXP News March 11, 2024
NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-completes-123000827.html
ABCOURT MINES | Red Cloud's Pre-PDAC 2024
Red Cloud TV
$NRXP - Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-133000763.html
FEAM...............MULN........................https://stockcharts.com/h-sc/ui?s=FEAM&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
DD...Big Picture For Silver Shows “Mother Of All” Cup & Handle Formations
The Price Of Silver Way Going Above $50, Plus Take A Look At Gold…
Those Holding Lots Of Gold Have Been Protected
Graddhy out of Sweden: If you think gold in US dollars is a non-event at the moment, consider this horrendous chart.
DD...$HGLD & $PGDC With One Of The Richest Highest Grade Silver Mine On Earth -
Patagonia Gold & Silver Mines Hard Asset Safety Bargain --
https://patagoniagold.com/wp-content/uploads/2022/10/Patagonia-Gold-Corporate-Presentation-Q4-2022-.pdf
https://investorshub.advfn.com/Patagonia-Gold-Corp.-HGLD-33022
https://www.patagoniagold.com
Get The Gold & Silver Mines Hard Asset Safety --
https://investorshub.advfn.com/Patagonia-Gold-Corp.-HGLD-33022
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171583317
ITS HAPPENING: ELON MUSK HAS SECRET MEETING WITH TRUMP AFTER DOMINANT VICTORY | 'GET READY...' 🔥
https://rumble.com/v4hqx7t--its-happening-elon-musk-has-secret-meeting-with-trump-after-dominant-victo.html
MIGRANT ARRESTS BEGIN IN NYC 🔥 NYPD BLUNT WARNING 🚨 GOV DEPLOY NATIONAL GUARD TO PETROL NYC SUBWAY
https://rumble.com/v4ht62o-migrant-arrests-begin-in-nyc-nypd-blunt-warning-gov-deploy-national-guard-t.html
MAGA Watch - GERALD CELENTE & Douglas Macgregor TV2
https://www.bitchute.com/video/LIdTVPbwpeqw/
IT BEGINS: MIGRANT CRIME WAVE SHOCKED THE NATION | TRUMP SLAMS BIDEN ON MIGRANT CRIME SPREE, BEATING
https://rumble.com/v4hlzr9-it-begins-migrant-crime-wave-shocked-the-nation-trump-slams-biden-on-migran.html
Gold vs M2 Money Supply:
Gold Massively Undervalued vs US Money Supply
$NEWS - Is Gold Setting Up for a Huge, Once in a Generation, Rally?
By Chris Vermeulen
Is there a generational opportunity coming to get into gold?
$GDHG News: Golden Heaven Group Holdings Ltd. Announces Guest Visits Increased During the 2024 Chinese Spring Festival Holiday
https://finance.yahoo.com/news/golden-heaven-group-holdings-ltd-130000542.html
SOAR......GGE......JAN.....BARK......MULN......https://stockcharts.com/h-sc/ui?s=SOAR&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=GGE&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=JAN&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=BARK&p=D&yr=0&mn=3&dy=0&id=p11960084343
$DTMXF - Competitor Monitoring
Keep a vigilant eye on competitors’ moves and customer feedback using AnalyticsGPT. This awareness allows you to seize market opportunities and craft strategies that position you ahead.
https://www.datametrex.com/analyticsgpt
$IVDN: Specifier Magazine has profiled new building code requirements for Continuous Insulation. Innovative Designs' Insultex® meets these new codes where competitive products do not. Insultex® also delivers an unmatched R-6 Rating. Learn more at: http://insultexhousewrap.com
$IVDN: Specifier Magazine has profiled new
— Innovative Designs, Inc (Stock: $IVDN) (@riccelli_joseph) March 4, 2024
building code requirements for Continuous Insulation. Innovative Designs' Insultex® meets these new codes where competitive products do not. Insultex® also delivers an unmatched R-6 Rating. Learn more at: https://t.co/LWNDwJcXDh https://t.co/iYnREarHQ2
$DTMXF a great opportunity today to buy, trading 5x its 10-day average volume.
Product Development
AnalyticsGPT provides insights into market trends and direct customer feedback, enabling you to refine products that align closely with customer needs.
https://www.datametrex.com/analyticsgpt
Followers
|
1893
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
182903
|
Created
|
11/19/12
|
Type
|
Free
|
Moderator $treet $inatra | |||
Assistants Smart Money smart money tracker acsmartmoney Smart Money Stocks __SmartMoney__ |
Posts Today
|
0
|
Posts (Total)
|
182903
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |